SHILPAMED Shilpa Medicare Ltd Investments/Divestments Announcement 2023 - Equity Shilpa Medicare Limited has received approval from CDSCO, New Delhi to manufacture and sell Lenvatinib Capsules in India under the brand name Lenshil. This new drug will offer flexibility of dosage and convenience for patients with specific cancer indications..Find Corporate Announcements for Press Releases, AGM, Insider Trading & SAST, Results and Corporate Action for Shilpa Medicare Ltd